'Striking the right balance' in targeting PPARγ in the metabolic syndrome: Novel insights from human genetic studies

PPAR Research

Volumn , Issue , 2007, Pages

  Gurnell, Mark ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; KR 62980; LEPTIN; NETOGLITAZONE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YM 440;

ADIPOGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; FLUID RETENTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GLUCOSE TRANSPORT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 42749099527     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2007/83593     Document Type: Review

References (114)

1. S. J. Olshansky sjayo@uic.edu D. J. Passaro R. C. Hershow A potential decline in life expectancy in the United States in the 21st century. New England Journal of Medicine 352 11 2005 1138 1145
2. C. L. Ogden Cogden@cdc.gov M. D. Carroll L. R. Curtin M. A. McDowell C. J. Tabak K. M. Flegal Prevalence of overweight and obesity in the United States, 1999-2004. Journal of the American Medical Association 295 13 2006 1549 1555
3. R. H. Eckel Robert.Eckel@UCHSC.edu S. M. Grundy P. Z. Zimmet The metabolic syndrome. The Lancet 365 9468 2005 1415 1428
4. J. Tuomilehto J. Lindström J. G. Eriksson Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine 344 18 2001 1343 1350
5. W. C. Knowler E. Barrett-Connor S. E. Fowler Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 346 6 2002 393 403
6. J. Auwerx PPARγ, the ultimate thrifty gene. Diabetologia 42 9 1999 1033 1049
7. B. M. Forman J. Chen R. M. Evans The peroxisome proliferator-activated receptors: ligands and activators. Annals of the New York Academy of Sciences 804 1996 266 275
8. H. Yki-Järvinen ykijarvi@cc.helsinki.fi Thiazolidinediones. New England Journal of Medicine 351 11 2004 1106 1118
9. J. A. Dormandy john.dormandy@btinternet.com B. Charbonnel D. J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macro vascular events): a randomised controlled trial. The Lancet 366 9493 2005 1279 1289
10. DREAM trial investigators Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 368 2006 9541 1096 1105
11. J. M. Lehmann L. B. Moore T. A. Smith-Oliver W. O. Wilkison T. M. Willson S. A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). Journal of Biological Chemistry 270 22 1995 12953 12956
12. V. Fonseca Effect of thiazolidinediones on body weight in patients with diabetes mellitus. American Journal of Medicine 115 8, supplement 1 2003 42 48
13. T. M. Larsen tml@kvl.dk S. Toubro A. Astrup PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? International Journal of Obesity 27 2 2003 147 161
14. Y. Guan C. Hao D. R. Cha Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Medicine 11 8 2005 861 866
15. S. Mudaliar A. R. Chang R. R. Henry Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocrine Practice 9 5 2003 406 416
16. I. Barroso M. Gurnell V. E. F. Crowley Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 6764 1999 880 883
17. A. K. Agarwal A. Garg A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. Journal of Clinical Endocrinology and Metabolism 87 1 2002 408 411
18. R. A. Hegele hegele@robarts.ca H. Cao C. Frankowski S. T. Mathews T. Leff PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51 12 2002 3586 3590
19. D. B. Savage G. D. Tan C. L. Acerini Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ Diabetes 52 4 2003 910 917
20. D. B. Savage M. Agostini I. Barroso Digenic inheritance of severe insulin resistance in a human pedigree. Nature Genetics 31 4 2002 379 384
21. G. A. Francis gordon.francis@ualberta.ca G. Li gangli@med.wayne.edu R. Casey Robin.Casey@CalgaryHealthRegion.ca Peroxisomal proliferator activated receptor-γ deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Medical Genetics 7 2006 3
22. R. A. Hegele hegele@robarts.ca E. Ur T. P. Ransom H. Cao A frameshift mutation in peroxisome-proliferator-activated receptor-γ in familial partial lipodystrophy subtype 3 (FPLD3; MIM 604367). Clinical Genetics 70 4 2006 360 362
23. M. Agostini E. Schoenmakers C. Mitchell Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metabolism 4 4 2006 303 311
24. H.-P. Guan T. Ishizuka P. C. Chui M. Lehrke M. A. Lazar lazar@mail.med.upenn.edu Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes and Development 19 4 2005 453 461
25. R. M. Evans G. D. Barish Y.-X. Wang PPARs and the complex journey to obesity. Nature Medicine 10 4 2004 355 361
26. G. D. Barish V. A. Narkar R. M. Evans evans@salk.edu PPARδ: a dagger in the heart of the metabolic syndrome. Journal of Clinical Investigation 116 3 2006 590 597
27. L. Fajas D. Auboeuf E. Raspé The organization, promoter analysis, and expression of the human PPARγ gene. Journal of Biological Chemistry 272 30 1997 18779 18789
28. L. Fajas J.-C. Fruchart J. Auwerx johan.auwerx@pasteur-lille.fr PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Letters 438 1-2 1998 55 60
29. H. Sundvold S. Lien Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1. Biochemical and Biophysical Research Communications 287 2 2001 383 390
30. B. Desvergne W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 5 1999 649 688
31. I. Tzameli H. Fang M. Ollero Regulated production of a peroxisome proliferator-activated receptor-γ ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. Journal of Biological Chemistry 279 34 2004 36093 36102
32. E. D. Rosen C.-H. Hsu X. Wang C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes and Development 16 1 2002 22 26
33. P. Tontonoz E. Hu B. M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79 7 1994 1147 1156
34. Y. Barak M. C. Nelson E. S. Ong PPARγ is required for placental, cardiac, and adipose tissue development. Molecular Cell 4 4 1999 585 595
35. E. D. Rosen P. Sarraf A. E. Troy PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 4 4 1999 611 617
36. N. Kubota Y. Terauchi H. Miki PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Molecular Cell 4 4 1999 597 609
37. M. Gurnell J. M. Wentworth M. Agostini A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. Journal of Biological Chemistry 275 8 2000 5754 5759
38. H. Bays L. Mandarino R. A. DeFronzo Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. Journal of Clinical Endocrinology and Metabolism 89 2 2004 463 478
39. M. Adams C. T. Montague J. B. Prins Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation 100 12 1997 3149 3153
40. M. Ristow D. Müller-Wieland A. Pfeiffer W. Krone C. R. Kahn Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New England Journal of Medicine 339 14 1998 953 959
41. E. Hu J. B. Kim P. Sarraf B. M. Spiegelman Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ Science 274 5295 1996 2100 2103
42. M. Adams M. J. Reginato D. Shao M. A. Lazar V. K. Chatterjee Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. Journal of Biological Chemistry 272 8 1997 5128 5132
43. M. Blüher R. Paschke pasr@medizin3.uni-leipzig.de Analysis of the relationship between PPAR-γ 2 gene variants and severe insulin resistance in obese patients with impaired glucose tolerance. Experimental and Clinical Endocrinology and Diabetes 111 2 2003 85 90
44. M. Agostini M. Gurnell D. B. Savage Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ Endocrinology 145 4 2004 1527 1538
45. K. Al-Shali H. Cao N. Knoers A. R. Hermus C. J. Tack R. A. Hegele robert.hegele@rri.on.ca A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy. Journal of Clinical Endocrinology and Metabolism 89 11 2004 5655 5660
46. Y.-S. Tsai H.-J. Kim N. Takahashi Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ Journal of Clinical Investigation 114 2 2004 240 249
47. S. L. Gray E. D. Nora J. Grosse Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor γ function (P465L PPARγ) in mice. Diabetes 55 10 2006 2669 2677
48. S. S. Deeb deeb@genetics.washington.edu L. Fajas M. Nemoto A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 20 3 1998 284 287
49. M. Stumvoll H. Häring The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 51 8 2002 2341 2347
50. M. M. Swarbrick C. M. L. Chapman B. M. McQuillan J. Hung P. L. Thompson J. P. Beilby A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-γ2 is associated with combined hyperlipidaemia in obesity. European Journal of Endocrinology 144 3 2001 277 282
51. B. A. Beamer C.-J. Yen R. E. Andersen Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47 11 1998 1806 1808
52. S. Masud S. Ye shu.ye@soton.ac.uk Effect of the peroxisome proliferates activated receptor-γ gene Pro12Ala variant on body mass index: a meta-analysis. Journal of Medical Genetics 40 10 2003 773 780
53. J. Luan P. O. Browne A.-H. Harding Evidence for gene-nutrient interaction at the PPARγ locus. Diabetes 50 3 2001 686 689
54. J. Robitaille J.-P. Després L. Pérusse M.-C. Vohl marie-claude.vohl@crchul.ulaval.ca The PPAR-γ P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Québec family study. Clinical Genetics 63 2 2003 109 116
55. T. M. Willson willsontm@glaxo.com J. E. Cobb D. J. Cowan The structure - activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. Journal of Medicinal Chemistry 39 3 1996 665 668
56. R. Mukherjee P. J. A. Davies D. L. Crombie Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386 6623 1997 407 410
57. S. M. Rangwala B. Rhoades J. S. Shapiro Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Developmental Cell 5 4 2003 657 663
58. W. He Y. Barak A. Hevener Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proceedings of the National Academy of Sciences of the United States of America 100 26 2003 15712 15717
59. A. L. Hevener W. He Y. Barak Muscle-specific Pparg deletion causes insulin resistance. Nature Medicine 9 12 2003 1491 1497
60. A. W. Norris L. Chen S. J. Fisher Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. Journal of Clinical Investigation 112 4 2003 608 618
61. K. Matsusue M. Haluzik G. Lambert Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. Journal of Clinical Investigation 111 5 2003 737 747
62. J. C. Florez jcflorez@partners.org J. Hirschhorn joel.hirschhorn@tch. harvard.edu D. Altshuler altshuler@molbio.mgh.harvard.edu The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annual Review of Genomics and Human Genetics 4 2003 257 291
63. A. Memisoglu amemisog@hsph.harvard.edu F. B. Hu S. E. Hankinson Prospective study of the association between the proline to alanine codon 12 polymorphism in the PPARγ gene and type 2 diabetes. Diabetes Care 26 10 2003 2915 2917
64. E. S. Tai D. Corella M. Deurenberg-Yap Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population. Journal of Lipid Research 45 4 2004 674 685
65. A. S. F. Doney B. Fischer J. E. Cecil Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to type 2 diabetes. Diabetologia 47 3 2004 555 558
66. L. Chao B. Marcus-Samuels M. M. Mason Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. Journal of Clinical Investigation 106 10 2000 1221 1228
67. K. Schoonjans J. Peinado-Onsurbe A.-M. Lefebvre PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO Journal 15 19 1996 5336 5348
68. B. I. Frohnert T. Y. Hui D. A. Bernlohr david-b@biosci.cbs.umn.edu Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. Journal of Biological Chemistry 274 7 1999 3970 3977
69. H.-P. Guan Y. Li M. V. Jensen C. B. Newgard C. M. Steppan M. A. Lazar A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nature Medicine 8 10 2002 1122 1128
70. J. Tordjman G. Chauvet J. Quette E. G. Beale C. Forest B. Antoine benedicte.antoine@biomedicale.univ-paris5.fr Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells. Journal of Biological Chemistry 278 21 2003 18785 18790
71. O. Vaccaro F. P. Mancini G. Ruffa Fasting plasma free fatty acid concentrations and Pro12Ala polymorphism of the peroxisome proliferator- activated receptor (PPAR) γ2 gene in healthy individuals. Clinical Endocrinology 57 4 2002 481 486
72. P. Peraldi M. Xu B. M. Spiegelman bruce_spiegelman@dfci.harvard.edu Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. Journal of Clinical Investigation 100 7 1997 1863 1869
73. C. M. Steppan S. T. Bailey S. Bhat The hormone resistin links obesity to diabetes. Nature 409 6818 2001 307 312
74. Q. Yang T. E. Graham N. Mody Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436 7049 2005 356 362
75. N. Maeda M. Takahashi T. Funahashi tohru@imed2.med.osaka-u.ac.jp PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 9 2001 2094 2099
76. R. S. Ahima ahima@mail.med.upenn.edu J. S. Flier Adipose tissue as an endocrine organ. Trends in Endocrinology and Metabolism 11 8 2000 327 332
77. T. P. Combs J. A. Wagner J. Berger Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143 3 2002 998 1007
78. R. K. Semple rks16@cam.ac.uk M. A. Soos J. Luan Elevated plasma adiponectin in humans with genetically defective insulin receptors. Journal of Clinical Endocrinology and Metabolism 91 8 2006 3219 3223
79. M. Iwata T. Haruta I. Usui Pioglitazone ameliorates tumor necrosis factor-α-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-γ Diabetes 50 5 2001 1083 1092
80. U. Smith S. Gogg A. Johansson T. Olausson V. Rotter B. Svalstedt Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB Journal 15 1 2001 215 220
81. J. Rieusset C. Chambrier K. Bouzakri The expression of the p85α subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetologia 44 5 2001 544 554
82. V. Ribon J. H. Johnson H. S. Camp A. R. Saltiel Thiazolidinediones and insulin resistance: peroxisome proliferator-activated receptor γ activation stimulates expression of the CAP gene. Proceedings of the National Academy of Sciences of the United States of America 95 25 1998 14751 14756
83. C. A. Baumann N. Chokshi A. R. Saltiel V. Ribon Cloning and characterization of a functional peroxisome proliferator activator receptor-γ-responsive element in the promoter of the CAP gene. Journal of Biological Chemistry 275 13 2000 9131 9135
84. I. J. Bujalska S. Kumar P. M. Stewart Does central obesity reflect "Cushing's disease of the omentum"? The Lancet 349 9060 1997 1210 1213
85. H. Masuzaki J. Paterson H. Shinyama A transgenic model of visceral obesity and the metabolic syndrome. Science 294 5549 2001 2166 2170
86. J. Berger joel_berger@merck.com M. Tanen A. Elbrecht Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity. Journal of Biological Chemistry 276 16 2001 12629 12635
87. B. S. Cha T. P. Ciaraldi L. Carter Peroxisome proliferator-activated receptor (PPAR) γ and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44 4 2001 444 452
88. C. Kausch J. Krützfeldt A. Witke Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochemical and Biophysical Research Communications 280 3 2001 664 674
89. A. A. Parulkar M. L. Pendergrass R. Granda-Ayala T. R. Lee V. A. Fonseca Nonhypoglycemic effects of thiazolidinediones. Annals of Internal Medicine 134 1 2001 61 71
90. F. Massiéra M. Bloch-Faure D. Ceiler Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. The FASEB Journal 15 14 2001 2727 2729
91. C. J. Östgren U. Lindblad Ulf.lindblad@smi.mas.lu.se O. Melander A. Melander L. Groop L. Rȧstam Peroxisome proliferator-activated receptor-γPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project. Journal of Hypertension 21 9 2003 1657 1662
92. S. J. Hasstedt Q.-F. Ren K. Teng S. C. Elbein Effect of the peroxisome proliferator-activated receptor-γ2 Pro12Ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. Journal of Clinical Endocrinology and Metabolism 86 2 2001 536 541
93. B. Isomaa P. Almgren T. Toumi Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 4 2001 683 689
94. J. Minamikawa S. Tanaka M. Yamauchi D. Inoue H. Koshiyama Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 83 5 1998 1818 1820
95. P. Tontonoz L. Nagy J. G. A. Alvarez V. A. Thomazy R. M. Evans PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 2 1998 241 252
96. L. Nagy P. Tontonoz J. G. A. Alvarez H. Chen R. M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell 93 2 1998 229 240
97. M. Ricote J. Huang L. Fajas Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 95 13 1998 7614 7619
98. C. Jiang A. T. Ting B. Seed seed@molbio.mgh.harvard.edu PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 6662 1998 82 86
99. M. Ricote A. C. Li T. M. Willson C. J. Kelly C. K. Glass cglass@ucsd.edu The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 6662 1998 79 82
100. J. S. Welch M. Ricote T. E. Akiyama F. J. Gonzalez C. K. Glass cglass@ucsd.edu PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proceedings of the National Academy of Sciences of the United States of America 100 11 2003 6712 6717
101. K. J. Moore E. D. Rosen M. L. Fitzgerald The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nature Medicine 7 1 2001 41 47
102. A. R. Tall P. Costet N. Wang Regulation and mechanisms of macrophage cholesterol efflux. Journal of Clinical Investigation 110 7 2002 899 904
103. G. Chinetti S. Lestavel V. Bocher PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 7 1 2001 53 58
104. A. Chawla Y. Barak L. Nagy D. Liao P. Tontonoz R. M. Evans PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Medicine 7 1 2001 48 52
105. E. Iwata I. Yamamoto T. Motomura The association of Pro12Ala polymorphism in PPARγ2 with lower carotid artery IMT in Japanese. Diabetes Research and Clinical Practice 62 1 2003 55 59
106. Z. C. Yan Z. M. Zhu C. Y. Shen Peroxisome proliferator-activated receptor γ C-161T polymorphism and carotid artery atherosclerosis in metabolic syndrome. Zhonghua Yi Xue Za Zhi 84 7 2004 543 547 Chinese
107. Y. Li M. A. Lazar Differential gene regulation by PPARγ agonist and constitutively active PPARγ2. Molecular Endocrinology 16 5 2002 1040 1048
108. M. J. Reginato S. T. Bailey S. L. Krakow A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. Journal of Biological Chemistry 273 49 1998 32679 32684
109. S. Rocchi F. Picard J. Vamecq A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Molecular Cell 8 4 2001 737 747
110. A. Shimaya E. Kurosaki R. Nakano R. Hirayama M. Shibasaki H. Shikama The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism: Clinical and Experimental 49 3 2000 411 417
111. P. Misra R. Chakrabarti R. K. Vikramadithyan PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic. Journal of Pharmacology and Experimental Therapeutics 306 2 2003 763 771
112. J. P. Berger joel_berger@merck.com A. E. Petro K. L. MacNaul Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator. Molecular Endocrinology 17 4 2003 662 676
113. K. R. Kim J. H. Lee S. J. Kim KR-62980: a novel peroxisome proliferator-activated receptor γ agonist with weak adipogenic effects. Biochemical Pharmacology 72 4 2006 446 454
114. K. Liu R. M. Black J. J. Acton III Selective PPARγ modulators with improved pharmacological profiles. Bioorganic and Medicinal Chemistry Letters 15 10 2005 2437 2440